Debbie Hulick is not only the co-chair of the 2014 American Craft Exposition and an active board member of the Auxiliary of NorthShore University HealthSystem, she’s also an ovarian cancer survivor. She was diagnosed with stage three ovarian cancer in June
2007. With three daughters of her own, raising awareness and raising funds for ovarian cancer research has become a passion. The American Craft Exposition (ACE), which provides funding to the research efforts of her own physician,
Dr. Gustavo Rodriguez, was a natural next step after she completed treatment at NorthShore.
Debbie tells us what led her to ACE and why research into this “silent” killer is so important:
What is your role with the American Craft Exposition (ACE)?
I am co-chair of the 2014 American Craft Exposition and an active board member of the Auxiliary of NorthShore University HealthSystem.
How did you learn about ACE? Why did you want to become involved?
After my treatment for stage three ovarian cancer at NorthShore was completed, I found out that ACE was funding the ovarian cancer research efforts of my physician, Gustavo Rodriguez, MD, for at-risk women. Having three daughters, it was very important
for me to become involved and help support this very significant cause. Today the funds raised at ACE are being applied to help better the lives of women in our community and I could not be more proud to have a hand in these efforts.
How does ACE help women with ovarian cancer?
Funds raised at ACE support pioneering research being conducted at NorthShore that is already showing promising results in preventing ovarian cancer in at-risk women. Ovarian cancer is called the “silent” killer because symptoms are easy to dismiss
and the disease is often diagnosed too late for effective treatment. More than 100 researchers are engaged in breast and ovarian cancer studies at NorthShore encompassing an array of multi-disciplinary programs addressing better methods for prevention, detection
What excites you most about this year’s exhibition? What will visitors see?
I am very excited that we have over 30 new artists exhibiting at ACE for the first time this year, including artist Thomas Marrinson. His brightly colored ceramic bowls create a stunning display and are sure to “wow” attendees! Besides Marrinson’s work, visitors
will have the opportunity to peruse and purchase stunning pieces from over 160 of the country’s finest craft artists. We also are bringing back our Craft in Action stage this year where visitors can watch both ceramic and wood demonstrations.
The American Craft Exposition is open to the public starting Friday, August 22nd. Visit
americancraftexpo.org for all of the details.
As part of National Parkinson’s Disease Awareness Month,
Demetrius Maraganore, MD, Chairman of Neurology at NorthShore, shared some of the findings of his ongoing research into the genetic factors that influence Parkinson’s disease progression and outcomes. He also tells us why research like this is so important
for Parkinson’s disease patients and their families:
Why is funding for and research into Parkinson’s disease so important?
It’s important because the treatments that we have available don’t prevent Parkinson’s disease (PD) or slow or halt its progression. PD is characterized by progressive motor and cognitive impairment. PD patients have a seven-fold increased risk of
nursing home placement and a two-fold increased risk of death. The annual cost of PD in the U.S. exceeds $23 billion. Presently 2% of people will develop PD during their lifetime, and the prevalence of PD is expected to double by 2030. The cumulative burden
of PD to society is and will be staggering. Our patients and their families deserve methods to predict, prevent and halt PD and those will only come through research.
How long have you been conducting research into Parkinson’s disease?
My research in Parkinson’s disease (PD) started in 1989, when I was an honorary clinical and research fellow to the late Professor C. David Marsden at the National Hospital for Neurology and Neurosurgery in London, England. Dr. Marsden was the founder of the
international Movement Disorders Society and its official journal, Movement Disorders. His associate, Professor Anita Harding, was a pioneer in the field of neurogenetics. Together, we launched the first genetic studies of Parkinson’s disease.
That has remained the focus of my research, including for 20 years on the faculty of the Mayo Clinic in Rochester, MN, and in the four years that I have been Chairman of Neurology at NorthShore. While my research at Mayo focused on identifying genetic factors
that contribute to the cause of PD, my research at NorthShore has focused on understanding how those genetic factors influence disease progression and outcomes. Our research aims to develop methods to predict outcomes in PD, and to use that information to
improve neurological health.
Why have you focused the bulk of your career on the study and treatment of Parkinson’s?
As a clinician, it’s very gratifying that there are many treatments that we can employ in the first many years to reduce the burden of the disease on patients and families. However, I recognize that the benefits of the existing treatments wane with
time, and I’m driven by the sense of urgency to identify the factors that contribute to the progression of Parkinson's disease. Our goal is to target those factors so that every individual patient can have the best possible outcome.
For more information on the NorthShore Neurological Institute and the research being done at NorthShore, click